牛牛AI助理已提取核心訊息
On February 1, 2024, Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the successful closing of its public offering, which was previously disclosed. The offering included 4,375,000 shares of common stock or pre-funded warrants and two classes of warrants to purchase up to 8,750,000 shares of common stock. The offering was priced at $2.06 per share and associated Public Warrants, and $2.059 per pre-funded warrant and associated Public Warrants. The gross proceeds from the offering amounted to approximately $9.0 million, before deducting placement agent fees and other offering expenses. Panbela intends to use the net proceeds for clinical development of its product candidates, working capital, business development, and other corporate purposes, which may include debt repayment. Following the offering, Panbela had 3,481,298 shares of common...Show More
On February 1, 2024, Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the successful closing of its public offering, which was previously disclosed. The offering included 4,375,000 shares of common stock or pre-funded warrants and two classes of warrants to purchase up to 8,750,000 shares of common stock. The offering was priced at $2.06 per share and associated Public Warrants, and $2.059 per pre-funded warrant and associated Public Warrants. The gross proceeds from the offering amounted to approximately $9.0 million, before deducting placement agent fees and other offering expenses. Panbela intends to use the net proceeds for clinical development of its product candidates, working capital, business development, and other corporate purposes, which may include debt repayment. Following the offering, Panbela had 3,481,298 shares of common stock issued and outstanding as of January 31, 2024. Roth Capital Partners served as the sole placement agent for the offering. The securities were offered pursuant to a registration statement that was declared effective by the SEC on January 26, 2024. Panbela's common stock is traded on The Nasdaq Stock Market under the symbol 'PBLA'.
2024年2月1日，臨床階段的生物製藥公司Panbela Therapeutics, Inc. 宣佈成功完成其公開募股，此前已披露該募股。此次發行包括4,375,000股普通股或預先注資的認股權證以及兩類認股權證，用於購買最多8,750,000股普通股。此次發行的定價爲每股2.06美元和相關的公共認股權證，每份預先注資的認股權證和相關的公開認股權證定價爲2.059美元。在扣除配售代理費和其他發行費用之前，此次發行的總收益約爲900萬美元。Panbela打算將淨收益用於其候選產品的臨床開發、營運資金、業務發展和其他公司用途，其中可能包括償還債務。發行後，截至2024年1月31日，Panbela已發行和流通了3,481,298股普通股。羅斯資本合夥人是此次發行的唯一配售代理人。這些證券是根據美國證券交易委員會於2024年1月26日宣佈生效的註冊聲明發行的。Panbela的普通股在納斯達克股票市場上市，股票代碼爲 “PBLA”。
2024年2月1日，臨床階段的生物製藥公司Panbela Therapeutics, Inc. 宣佈成功完成其公開募股，此前已披露該募股。此次發行包括4,375,000股普通股或預先注資的認股權證以及兩類認股權證，用於購買最多8,750,000股普通股。此次發行的定價爲每股2.06美元和相關的公共認股權證，每份預先注資的認股權證和相關的公開認股權證定價爲2.059美元。在扣除配售代理費和其他發行費用之前，此次發行的總收益約爲900萬美元。Panbela打算將淨收益用於其候選產品的臨床開發、營運資金、業務發展和其他公司用途，其中可能包括償還債務。發行後，截至2024年1月31日，Panbela已發行和流通了3,481,298股普通股。羅斯資本合夥人是此次發行的唯一配售代理人。這些證券是根據美國證券交易委員會於2024年1月26日宣佈生效的註冊聲明發行的。Panbela的普通股在納斯達克股票市場上市，股票代碼爲 “PBLA”。
有用
沒用